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Objectives: To estimate medical expenditure for people with diabetes covered 
by Urban Employee Basic Medical Insurance (UEBMI) in Fujian. MethOds: Claims 
data were extracted from UEBMIF database during 2012.1. 1 to 2012.12.31. People 
with diabetes were identified by keyword – diabetes. To estimate expenditures, we 
used Sum_All Medical method. Descriptive analyses were conducted by using EXCEL 
2010. Results: In 2012, one of the Fujian UEBMI database recorded claims data of 
240079 patients, including 5953 with diabetes (2.48%), among which 68.81% were male 
and 91.03% were age over 50. The number of General Outpatient (GO)/Catastrophic 
Outpatient (CO)/inpatient with diabetes was 5196/4964/2325. GO/CO with diabetes 
visited physicians averagely 24.13/46.02 times, almost 60% of the visits happened in 
tertiary hospitals. People with diabetes each used inpatient services 1.70 times; the 
mean number of LOS was 16.52 days. Total Direct Medical Expenditure for people with 
Diabetes (TDMED) was CNY 132 million (16.33% of total direct medical expenditure); 
out-of-pocket spending accounted for 27.20%. GO/CO/inpatient medical expenditures 
were CNY 3824.16/7960.88/31365.25 per person and CNY 158.49/172.97/18396.62 per 
visit. Expenses for medicine was CNY 89 million (67.01% of TDMED), only CNY 17 mil-
lion (13.03% of TDMED) was spent on anti-glycaemic medicine. 94.56% of people with 
diabetes took prescribed anti-glycaemic medicine, including OAD (88.34%), insulin 
(41.21%) and traditional Chinese medicine (23.13%). For CO, 47.26% of the visits were 
due to diabetes and the medical expenditure accounted for 43.40%. Among hospi-
talized people with diabetes, only 10.68% of their primary diagnoses were diabetes. 
Inpatient with diabetes whose primary diagnoses were diabetes consumed less health 
care resources (average LOS/medical expenditure per person/medical expenditure 
per visit) than those whose primary diagnoses were diabetic complications or other 
diseases (15.47days/CNY 14567.57/CNY 12481.90 vs. 16.65days/CNY 27666.67/CNY 
19161.66). cOnclusiOns: Diabetes, as one of the major chronic diseases, consumed 
a large amount of medical resources in Fujian. Majority of direct medical expenditure 
were spent on treating diabetic complications and other diseases.
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Objectives: The aim of this study was to assess the indirect costs associated with 
types 1 and 2 diabetes mellitus (DM) from the perspective of the Social Insurance 
Institution (ZUS) in Poland. MethOds: The estimates were based on data from the 
year 2012 concerning absence from work due to the illness (sick leave) the amount 
of short term disability, the sufferers of which claim rehabilitation benefit, and the 
amount of permanent (or long term) disability, the sufferers of which claim dis-
ability pension. Costs were presented in Polish zloty (PLN). Results: Total indirect 
costs of DM types 1 and type 2 in the year 2012 in Poland were 59 013 912 PLN and 
66 597 701 PLN, respectively. The highest component of indirect costs of DM type 1 
was sick leave (61%). Long and short term disability costs constitute 28% and 11% 
of total indirect costs of DM type 1, respectively. A slightly different situation was 
reported in the case of type 2 diabetes: long term disability costs were only 1% of 
total indirect costs, and short term disability had a slightly larger part of indirect 
costs (less than 5%). The highest component of indirect costs of DM type 2 was sick 
leave (95%). One sick leave of a person with types 1 or 2 diabetes generated a cost 
of lost productivity equal to 1 771 PLN or 1 585 PLN, respectively. The cost of dis-
ability pension per one person was higher than rehabilitation benefit, and equalled 
41 398 PLN compared with 17 249 PLN (the average value of one short and long 
term benefit payment was the same for both types of diabetes). cOnclusiOns: 
DM in Poland generated high indirect costs. The main component was sick leave; 
rehabilitation benefit and disability pension generated much lower costs for Social 
Insurance Institution.
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Objectives: Type 2 Diabetes Mellitus (T2DM) is a worldwide prevalent chronic 
disease, related to high morbidity and mortality, and to significant socioeconomic 
costs. However, the magnitude of cost varies significantly among empirical studies. 
The objective of this literature review is to identify the main drivers that influ-
ence the costs of T2DM. MethOds: We searched relevant databases for studies 
estimating T2DM costs, published in English and Spanish in the USA and Europe 
(1995-2014). Search terms included “diabetes”, “costs”, “burden”, and “economic 
impact”. No exclusion was made based on study design. Cost drivers and differences 
in methodologies across studies were identified. Results: A total of 25 papers 
were included out of 618 relevant titles identified. Costing methodologies and cost 
drivers vary significantly causing important variations in results. The main differ-
ence in methodology refers to estimating T2DM costs versus the costs of people 
living with T2DM, which include all direct sanitary costs -whether directly related 
to T2DM or not- and may increase total costs by up to 74%. Direct sanitary costs 
range between 40% and 75% of total costs depending partially on whether produc-
tivity losses and caregiving are considered. The relative weight of hospitalizations 
range between 20% and 60% of sanitary costs depending on the categories included. 
Pharmacologic costs range between 13% and 46%, which include antidiabetic drugs 
and treatments for complications derived from poor control. Optimal glycemic con-
trol reduces costs but is not always considered in the studies. Microvascular and/
or macrovascular complications and hypoglycemic events increase total cost per 
patient. cOnclusiOns: Differences in costing methodology, the type of cost cat-
egories included in the analysis and the source of data greatly influence the results 
of the studies and impede reaching accurate conclusions regarding the cost of T2DM. 
Designing standardized costing methodology guidelines would help future studies 
estimate the real burden of T2DM.
Objectives: To determine the clinical (compliance, metabolic control, hypoglycae-
mia and cardiovascular events [CVE]) and economic (resources and costs) impact 
of metformin in combination with dipeptidyl peptidase-4 inhibitors (DPP4-I) or 
sulfonylureas in patients with type 2 diabetes. MethOds: Design: Multicentre, 
observational retrospective study. Patients aged ≥ 30 years under treatment with 
metformin who initiated a second oral antidiabetic treatment in 2008-2009 were 
evaluated. Two study groups were established: a) metformin + DPP4-I, b) met-
formin + sulfonylureas. Main measures: comorbidity, metabolic control (HbA1c < 
7%), compliance and complications (hypoglycaemia, CVE). Patients were followed 
for 2 years. The cost model considered direct (primary/specialised care) and indi-
rect (productivity) health care costs. Statistical analysis: logistic regression models 
and ANCOVA, p < 0.05. Results: We recruited 1,405 patients (men age 67.1 years, 
56.2% male) of whom 37% initiated a second treatment with DPP4-I and 63% with 
sulfonylureas. At 2 years follow-up, patients treated with DPP4-I showed better 
compliance (70.3% vs 60.6%), better metabolic control (64.3% vs 60.6%), and a lower 
proportion of hypoglycaemia (13.9% vs 40.4%) (p < 0.05). The mean unit costs of the 
total adjusted costs were € 2,341 vs € 2,512, respectively; p = 0.038. Rates of CVE 
and renal failure were 3.7% vs 6.4%; p = 0.027. Vildagliptin was the most commonly 
used DPP4-I. cOnclusiOns: Sulfonylureas were the most frequently used drugs 
for the treatment of diabetes. Patients treated with DPP4-I had better compliance 
and control of diabetes, with lower rates of hypoglycaemia and CVE, resulting in 
reduced health care costs.
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Objectives: To estimate the impact of diabetic complications on immediate and 
long-term direct medical costs in Hong Kong. MethOds: A retrospective cohort 
study was conducted among 137,634 diabetic subjects from a territory-wide admin-
istrative database over six years (2008-2013). The trends of annual direct medi-
cal costs were analyzed by three groups: group 1) subjects without complications 
over study period; group 2) subjects with existing complications at baseline; and 
group 3) subjects developing new complications during follow-up. We employed 
panel data regression to investigate the impact of each diabetic complication on 
direct medical costs in the event year and subsequent years, adjusting for age and 
Charlson Comorbidity Score. Results: We found 10,322 subjects with existing 
diabetic complications at baseline (January 1st, 2009), and 14,349 newly developed 
diabetic complications over 5 years. The annual direct medical costs increased from 
$US4,629 to $US15,585 in the new complications group, which is substantially higher 
than the modest rise in the no complication group (from $US1,157 to $US1,984). The 
annual direct medical cost of baseline case was $US1,062 (62 year-old, no compli-
cation, Charlson Comorbidity Score= 0). After adjusting for age and comorbidity, 
compared to the baseline case, the multipliers of annual direct medical costs in 
the event year were: acute myocardial infarction (AMI) 10.61; other ischemic heart 
disease (IHD) 3.67; congestive heart failure (CHF) 8.46; stroke 10.17; sight threaten-
ing diabetic retinopathy (STDR) 3.41; blindness 2.78; end stage renal disease (ESRD) 
12.16; peripheral vascular disease (PVD) 3.00; amputation: 3.48. The multipliers in 
subsequent years were: AMI 1.45; other IHD 1.32; CHF 1.86; stroke 1.37; STDR 2.16; 
blind 1.32; ESRD 1.86; PVD 1.42; amputation 1.32. cOnclusiOns:  There were wide 
variations in direct medical cost in event year and subsequent years across differ-
ent major complications. These data would be useful for economic evaluations of 
diabetes prevention or treatment programs.
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Objectives: This study aimed to analyze the direct medical cost of diabetes related 
micro- and macrovascular complications in Korean people with diabetes melli-
tus. MethOds: Using the Health Insurance Review & Assessment Service-National 
Patients Sample (about 1.3 million patients), which was a stratified sampling from 
the entire population (about 46 million persons) under the Korean national health 
security system (2011), estimation of direct medical cost complication for patients 
who have diabetes related chronic complications were performed. We used the 
6th revision of Korean Standard Classification of Diseases (KCD-6) which had been 
developed with the reference of the 10th version of International Classification (ICD-
10). All statistical analyses were performed using the Statistical Analysis System 
(SAS, version 9.3). Results: The mean age of the subjects was 61.4 years, 52.1% were 
male and 47.9% were female. Of the 91,463 patients with DM, 20,584 patients (22%) 
had at least one microvascular or macrovascular complication, 70,879 patients (78%) 
had no complication. The average annual direct medical cost in patients who had 
no complications was 351,660 won in 2011. The average annual direct medical cost 
in patients who had microvascular complications such as retinopathy, nephropathy, 
neuropathy was 506,160 won, 1.4 times higher than without DM complications, who 
had macrovascular complications such as MI, CVA, ESRD was 1,362,928 won, 3.8 
times higher than without DM complications. cOnclusiOns: Diabetic complica-
tions have a substantial impact on the direct medical costs of DM patients. As the 
number of people with diabetes continues to rise, early detection of the disease and 
implementation of timely and appropriate therapeutic strategies could decrease 
the burden of diabetes chronic complications and also huge related expenditures.
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inpatient ($3,051 vs. $424, p< 0.0001), ER ($127 vs. $39, p< 0.0001), physician office 
($2,934 vs. $875, p< 0.0001), outpatient ($3,299 vs. $971, p< 0.0001), pharmacy ($610 
vs. $224, p< 0.0001) and total costs ($6,958 vs. $1,618, p< 0.0001) than the comparison 
cohort. cOnclusiOns: Study results suggest that patients diagnosed with T2DM 
utilized more health resources and incurred four times higher costs compared to 
those without a T2DM diagnosis.
PDB55
MeDIcal exPenDItures assocIateD wIth tyPe 2 DIaBetes MellItus In 
jaPan: a large claIMs DataBase stuDy
Fukuda H.1, Ikeda S.2, Shiroiwa T.3, Igarashi A.4, Fukuda T.3
1Kyushu University, Graduate School of Medical Sciences, Fukuoka, Japan, 2International 
University of Health and Welfare, Otawara City, Tochigi, Japan, 3National Institute of Public 
Health, Saitama, Japan, 4University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, 
Japan
Objectives: The objective of the study was to estimate the excess costs associated 
with type 2 diabetes mellitus (T2DM) and diabetes-related complications in Japan 
through the use of a large claims database. MethOds: We performed a retrospec-
tive cohort analysis using a large commercial claims database obtained from the 
Japan Medical Data Center Co., Ltd. (Tokyo, Japan). Data from the period between 
January 2005 and June 2012 were analyzed. Patients diagnosed with T2DM were 
identified using the International Classification of Diseases 10th revision (ICD-10) 
diagnosis codes E11–E14, with the month of initial diagnosis designated as the 
index month. Cost and health care utilization data from claims for outpatient, 
inpatient, and dispensing services during the study period were summarized to 
per-patient-per-month (PPPM) levels. Costs were calculated from the perspective of 
a public health care payer. Diabetes-related complications were identified through 
the occurrence of the following diseases after the index month and/or their associ-
ated treatment: retinopathy, nephropathy, neuropathy/extremity disease, ischemic 
heart disease, and cerebrovascular disease. Regression-adjusted medical costs 
associated with each health state of T2DM were estimated using a fixed-effects 
model. Results: A total of 8,063,139 PPPM records from 152,791 T2DM patients 
were identified and examined. The average follow-up duration per patient was 
52.8 months. The average incremental cost for T2DM was US$123 PPPM. The 
average incremental costs for diabetes-related complications were US$94 
(retinopathy without surgery), US$1,933 (retinopathy with surgery), US$17 (renal 
proteinuria), US$319 (renal failure), US$3,677 (dialysis), US$131 (neuropathy 
and/or extremity disease without surgery), US$4,498 (neuropathy and/or 
extremity disease with surgery), US$93 (ischemic heart disease without sur-
gery), US$13,280 (ischemic heart disease with surgery), US$56 (cerebrovascular 
disease with surgery), and US$2,605 (cerebrovascular disease with hospitaliza-
tion). cOnclusiOns: These estimates of incremental medical expenditure in rela-
tion to health state may contribute to economic evaluations of various aspects 
of health care in Japan.
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Objectives: To analyse the annual health care costs of patients with type 2 diabetes 
in Flanders from the perspective of the health care system and to assess the impact 
of comorbidities on total cost. MethOds: Study participants were selected from 
the Independent Sickness Fund database on consumption of hypoglycemic agents 
and invited to participate in a clinical trial on diabetes education. Information on 
resource utilization during 12 months preceding inclusion was extracted from the 
database and combined with baseline clinical assessment data. Total health care 
costs consisted of costs paid by the public health insurance and patient co-payments 
and was analyzed as function of reported comorbidities through stepwise multiple 
regression. Results: 574 patients agreed to participate. Mean age was 64 years (35 - 
75) and type 2 diabetes was diagnosed since 7 years on average. 62% were men, 86% 
were treated with oral antidiabetics. 38% reported to have at least one comorbidity. 
30% were hospitalized in the study period. Hospitalizations accounted for 41% of 
the total cost, followed by outpatient prescription medications (22%) and physician 
consults (8%). The mean (95% CI) health care cost was € 4,522 (€ 3,799 to € 5,245). The 
mean annual cost of patients with no comorbidities was € 3,357 (€ 2,599 to € 4,116) 
and increased till € 4,750 (€ 3,511 to € 5,990) for those with one comorbidity (p= .001) 
and till € 7,303 (€ 3,909 to € 10,697) and € 9,868 (€ 4,685 to € 15,051) for those with two 
and three comorbidities respectively (p= .039 and. 057). Coronary heart disease was 
the main contributor to the cost variability (R2= 0.063, p= .000). cOnclusiOns: Our 
study updates the knowledge on the actual annual cost of diabetes treatment in 
Flanders. Combination of clinical information and health insurance claims data 
allowed analysis based on the patient medical condition. The high marginal cost 
of people with comorbidities emphasises the importance of prevention for people 
diagnosed with type 2 diabetes.
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Objectives: To estimate the multimorbity associated with diabetes mellitus 
type 2 and its relation to pharmaceutical cost in a primary health care set-
ting. MethOds: Cross-sectional study during 2012. A health region of 5,150,540 
population was analysed to determine the diabetic individuals. 350,015 diabetic 
individuals were identified through clinical codes using the ICD-9-MC classifica-
tion and the 3M Clinical Risk Groups software. We analyzed the consumption of 
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Objectives: The aim of this study is to assess for 2012 the cost of diabetes from a 
payer perspective, based on the French health insurance database and using two 
different approaches (top down versus bottom-up). MethOds: Using information 
about 60 millions of individuals from the general scheme insurance database (85% 
of the French population), we developed algorithms to identify all people who 
received care for each of 56 groups of diseases or medical events or treatments, 
which are frequent, severe and/or costly. Algorithms have been applied to each 
patient. For diabetes, we used ICD-10 diagnoses for long-term chronic diseases, 
reimbursement for anti-diabetic drugs. Costs of all reimbursed expenditures (out-
patient/inpatient care, disability/sickness benefits) were extracted per individual. 
The top-down method allocated expenditure to each of the 56 diseases based 
on the average expenditure by disease calculated for individuals with only one 
disease. All expenditures were thereafter extrapolated to the whole population 
to fit national health account aggregates. For the bottom-up approach, diabetes 
expenditures were estimated by identifying finely in our database expenditure 
items which are partly or wholly directly related to diabetes according to expert 
judgment. Results: Based on the top-down approach, among the 146 billion 
euros of expenditures reimbursed by national health insurance (all insurance 
schemes) in 2012, 7. 5 billion (5%) are attributable directly to diabetes. Expenditures 
for chronic renal insufficiency and cardio-vascular disease, frequent diabetes com-
plications, have been assessed separately. Drugs and medical devices (3.8 billion € ) 
represents more than 50% of the diabetes expenditures, other outpatient care 
34% (2.5 billion), inpatient care 9% (700 millions) and disability/sickness benefits 
7% (500 millions). Based on our bottom-up, around 8 billion would be directly 
attributable to diabetes. cOnclusiOns: Our study provides estimation of the 
cost of diabetes from a payer perspective, according to two different approaches 
but with concordant results.
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Objectives: To determine the direct cost of health care technologies used for 
treatment of diffuse toxic goiter in Ukraine. MethOds: We made the retrospec-
tive analysis of 52 patients’s medical records with DTG that were hospitalized to 
the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). The 
method of pharmacoeconomic analysis “cost of illness” was used to estimate the 
cost of health care for patients with DTG. We have made calculations of costs: the 
cost of laboratory analysis, the cost of instrumental analysis, the cost of drug treat-
ment, doctor’s consultations, costs of patient’s stay in hospital. While determining 
the direct costs of medical services in monetary terms we used the rates for medical 
services that were in Ternopil University Hospital. Results: The study found that 
among the patients there were 11 (21.15%) men and 41 (78.85%) women aged 20 to 
65 years (46.88±8.9). All patients have got to the hospital in stage of medication sub-
compensation. The average duration of stay in hospital for patients was 10.67±2.07 
days. The total cost of laboratory tests was EUR 1,555.53. The costs of instrumental 
methods of patients examination amounted EUR 204.25. The cost of consultations 
by specialists was EUR 285.97. In determining the amount of direct costs for medi-
cines we found that the cost of drug treatment of the underlying disease is EUR 
211.83, the cost of drug therapy of DTG complications is EUR 1,163.64. Total cost of 
patients stay in hospital was EUR 3,513.45. After calculation of all direct costs we 
determined that the total cost of DTG per patient is EUR 133.36 per course of treat-
ment. cOnclusiOns: In the cost structure of health care provision for patients 
with diffuse toxic goiter the most significant costs were spent for laboratory tests 
and for patient’s stay in hospital. The presence of underlying disease complications 
significantly increases cost of drugs.
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Objectives: To evaluate the economic burden and health care utilizations of Type 
2 diabetes mellitus (T2DM) among U.S. veteran patients. MethOds: T2DM patients 
(International Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] 
diagnosis codes 250.x0, 250.x2) were identified using the U.S. Veterans Health 
Administration Medical SAS datasets (01OCT2008-31SEP2011). The first diagnosis 
date was defined as the index date. A comparison cohort of patients without a T2DM 
diagnosis but of the same age, region, gender and index year were identified and 
matched according to baseline Charlson Comorbidity Index scores, with a randomly 
chosen index date to minimize selection bias. Patients in both cohorts were required 
to be at least age 18 years, with 1-year continuous health plan enrollment pre- and 
post-index date. Baseline body mass index (BMI) and glycated hemoglobin (HbA1c) 
values and follow-up health care costs and utilizations were compared using 1: 
1 propensity score matching (PSM). Results: A total of 1,211,748 T2DM patients 
were identified for study. T2DM patients had significantly higher HbA1c (7.25 vs. 
5.78, p< 0.0001) and BMI (31.75 vs. 29.16, p< 0.0001) results during the baseline period. 
After 1: 1 PSM, each cohort included 323,962 patients, with well-balanced baseline 
demographic and clinical characteristics. A higher percentage of T2DM patients had 
inpatient admissions (8.65% vs. 1.58%, p< 0.0001), emergency room (ER) (13.12% vs. 
4.44%, p< 0.0001) and physician office visits (99.54% vs. 45.22%, p< 0.0001) and pre-
scription fills (84.55% vs. 45.43%, p< 0.0001). The T2DM cohort also incurred higher 
